PRIORITY SERVICES

The Brazilian Registry of Clinical Trials (ReBEC) presents the new fast tracks for clinical research and observational studies on INDIGENOUS PEOPLE AND TRADITIONAL COMMUNITIES and on NEGLECTED TROPICAL DISEASES (NTDs). Fast-track can reduce the normal approval period for clinical trials to less than 48 hours, if the documentation, information and any mandatory changes requested are provided by the registrant.

The already existing fast-tracks and the attendance to other studies will not be interrupted. Priority care is granted with a view to accelerating clinical research in epidemiological emergency situations and/or studies with the potential to reduce socioeconomic inequalities, keeping the perspective aligned with the forefront of ethics and transparency, diplomacy in health, scientific collaboration and diversity and specificities of recruitment and health care.

FAST-TRACKS IN OPERATION:

I - Indigenous Peoples, Traditional Communities, Human Migration and Refugee Movements – clinical research and observational studies dedicated to or preferably addressing traditional communities (quilombola, caiçara, faxinalense, among others), Indigenous peoples (within or outside legally demarcated territories), and refugee groups, taking into account the specificities established by regulation, on a case-by-case basis.

II - Neglected Tropical Diseases – Leprosy, Tuberculosis, Leishmaniasis, Schistosomiasis, Scabies, Chagas disease, Intestinal parasitoses, Viral hepatitis, Trachoma, Onchocerciasis, Human rabies transmitted by dogs.

III - National and International Public Health Emergencies – Mpox, Covid-19.

IV - Arboviruses – Zika, Dengue, Chikungunya, Malaria, Yellow fever.

V - WHO Prioritized Pathogens for Latin America – Studies dealing with World Health Organization prioritized pathogens for Latin America, as listed in the document "PATHOGENS PRIORITIZATION - A SCIENTIFIC FRAMEWORK FOR EPIDEMIC AND PANDEMIC RESEARCH PREPAREDNESS" (Health Emergencies Programme, 2024) – Lassa fever, Cholera, Black Death (Plague), Bacillary dysentery or Shigellosis, Salmonella, Pneumonia, Urinary tract infection, MERS-CoV, SARS, Ebola virus (EVE), Marburg virus (MVE), Ebola virus (EVE) Sudan subtype, Hantavirus pulmonary syndrome (HPS), Hemorrhagic fever with renal syndrome (HFRS), Crimean-Congo hemorrhagic fever, Influenza A H1, Influenza A H2, Influenza A H3, Avian influenza (Influenza A H5N1), Avian influenza (Influenza A H6), Avian influenza H7 (Avian influenza H7), Avian influenza H10 or Avian influenza H10, Nipah disease, Viral hemorrhagic disease, Poliomyelitis, Hand-foot-and-mouth disease, Herpangina, Viral meningitis, Smallpox, Mpox, Human Immunodeficiency Virus (HIV), Venezuelan equine encephalitis (VEE).

VI - WHO Prioritized Prototype Pathogens for Latin America – Studies dealing with World Health Organization prioritized prototype pathogens for Latin America, as listed in the document "PATHOGENS PRIORITIZATION - A SCIENTIFIC FRAMEWORK FOR EPIDEMIC AND PANDEMIC RESEARCH PREPAREDNESS" (Health Emergencies Programme, 2024) – Recombinant mastadenovirus, Mastadenovirus blackbeardi serotype 14, Mammarenavirus juninense, Mammarenavirus lujoense, Mamastrovirus virginiaense, Orthobornavirus bornaense, Orthoflavivirus encephalitidis, Orthoflavivirus nilense, Orthohepadnavirus hominoidae genotype C, Paslahepevirus balayani genotype 3, Protoparvovirus carnivoran, Orthobunyavirus oropoucheense, Phlebovirus riftense, Orthopicobirnavirus hominis, Enterovirus alphacoxsackie 71, Enterovirus deconjuncti 68, Metapneumovirus hominis, Orthopoxvirus vaccinia, Genus Vesiculovirus, Genus Rotavirus, Orthoreovirus mammalis.

VII - Studies on the impacts of climate change, the effects of scientific denialism, and health misinformation -The physical, mental, and social consequences of environmental and climate changes on human populations; The impact of extreme weather events and environmental degradation on infectious, chronic, or emerging diseases; The influence of denialist narratives and misinformation in Health on adherence to preventive measures, vaccination, treatments, and risk behaviors, as well as the physical and mental outcomes for human beings and populations.

INSTRUCTIONS:

We recommend reading the Registrant Handbook. Material available at LINK.

1. Register or log in and normally fill out the forms in Portuguese and English. For English, in case of difficulty, use the Google Translate tool (or another free translation tool).
2. Attach the mandatory ethics committee documentation and submit the form.
3. Register the service number on your Whatsapp. Send a message with your name and login. IT IS NOT NECESSARY NOR RECOMMENDED TO SEND YOUR PASSWORD.
4. A reviewer will respond to you. Choose the service modality: chat, audio recordings or voice call by appointment.
5. Your form will be proofread in both languages. Follow the remaining guidelines to finalize the approval.

CONTACTS:

ReBEC support is provided exclusively by official online channels.

Service channels:
* IA ReBEC@ (virtual assistant): automated service 24 hours a day, 7 days a week
* Humanized chat: from Monday to Friday, from 8 a.m. to 12 p.m. (Brasília time)
* Institutional WhatsApp / Dedicated line: +55 21 97203-4750
Service from Monday to Friday, from 9 a.m. to 4 p.m. (Brasília time)

Priority and/or urgent administrative demands outside the file schedule may be submitted to: plantao.rebec@gmail.com

We recommend that all requests be accompanied by a login, linked email or study registration number. (RBR-xxxxxxx), when applicable, for agility in attention.

ABOUT REBEC:

The Brazilian Registry of Clinical Trials (ReBEC) is a free access virtual platform for recording experimental and non-experimental studies carried out on human beings and conducted in Brazilian territory, by Brazilian and foreign researchers. ReBEC is a joint project of the Ministry of Health (DECIT/MS), the Pan American Health Organization (OPAS) and the Oswaldo Cruz Foundation (FIOCRUZ). ReBEC's Executive Committee is composed of the aforementioned institutions and the National Health Surveillance Agency (ANVISA).

07/13/2026  |  Marissa Plescia  |   MedCity News

https://medcitynews.com/2026/07/nearly-200-organizations-back-bill-seeking-to-increase-access-to-clinical-trials/ 

Nearly 200 healthcare and patient advocacy organizations endorsed the bipartisan Clinical Trial Modernization Act, which seeks to reduce financial barriers and expand access to clinical trials for underrepresented patients.

In a Monday letter, 195 patient advocacy, public health and healthcare professional organizations endorsed the Clinical Trial Modernization Act, which seeks to increase access to clinical trials for underrepresented groups.

The organizations include the American Cancer Society Cancer Action Network, the American Lung Association, the American Pharmacists Association, the National Alliance on Mental Illness, the National Black Nurses Association and more.

The Clinical Trial Modernization Act was introduced in the Senate by Senators Mark Warner (D-Virginia) and Tim Scott (R-South Carolina) and in the House by Representatives Raul Ruiz (D-California) and August Pfluger (R-Texas). It would reduce economic barriers to participating in clinical trials by permitting sponsors to provide financial support for travel, lodging, childcare, copays and coinsurance. It would also allow sponsors to provide remote patient monitoring tools at no cost to support remote participation in clinical trials.

In addition, it would expand enrollment of underrepresented groups by allowing the Department of Health and Human Services to provide grants for community education, outreach and recruitment. Lastly, the bill would protect patients from financial hardship by excluding up to $2,000 in financial assistance from federal income taxes and eligibility calculations for safety-net programs like Medicaid.

07/08/2026  |  WHO/World Health Organization

https://www.who.int/news/item/08-07-2026-who-calls-for-urgent-action-as-new-cancer-cases-are-projected-to-nearly-double-by-2050 

Millions of people are facing physical, emotional and financial toll of cancer, a disease that claims more than 26 000 lives every day, according to a report released today by the World Health Organization (WHO). With an estimated 20.6 million new cases and close to 10 million deaths annually, cancer remains the second leading cause of death globally, after cardiovascular disease.

Reversing this trend will require a fundamental shift towards a people-centred approach that responds to the health needs and lived experiences of affected people and communities. Without urgent action, annual cancer cases are projected to rise to nearly 35 million by 2050.

The WHO Global Status Report on Cancer 2026, developed jointly with the International Agency for Research on Cancer (IARC), provides comprehensive analysis of progress across key areas such as political commitment, cancer prevention – particularly through tobacco control and vaccination programmes – and investment in treatment.

However, the report also reveals persistent and widening inequities in access to prevention, diagnosis, treatment and supportive care, leaving millions of people without the services they need. Its analysis shows that while 87% of women with breast cancer survive at 5 years after their diagnosis in high-income countries, only about 42% do so in low-income countries. Fewer than one in three countries currently include cancer care in their universal health coverage packages.

"Cancer is a deeply personal disease that touches nearly all of us. But whether a person survives cancer should never depend on where they were…

07/12/2026 | Priscila Gava Mazzola | Sechat

https://sechat.com.br/coluna/icrs-2026-um-evento-de-excelencia-cientifica-e-colaboracao 

The congress held in Dijon showcased the sector's maturity, uniting basic research, artificial intelligence, and clinical practice to accelerate the development of new treatments.

Attending an international congress is always an opportunity to stay up to date. Yet, some events go further, becoming spaces where cutting-edge science, collaboration, and the exchange of experiences occur genuinely. This was the impression left by the 36th edition of the International Cannabinoid Research Society (ICRS) conference, held in Dijon, France.

The program reflected the maturity that cannabinoid research has achieved over recent decades. Over four days, discussions ranged from molecular mechanisms and the discovery of new therapeutic targets to clinical trials, translational pharmacology, artificial intelligence applied to drug development, neuroscience, metabolism, pain, inflammatory diseases, cancer, and evidence-based medicine. The agenda also included sessions dedicated to medicinal chemistry, chemical biology, pharmacology, clinical research, and regulatory science, demonstrating how different fields converge to address the same scientific questions. It became evident that the field is evolving toward an increasingly translational approach, bridging the gap between basic research, clinical applications, and pharmaceutical development.

Another notable aspect was the event's organization. Activities ran extremely smoothly, featuring well-structured thematic sessions, keynote lectures, oral presentations, rapid communications, and poster sessions. This format fostered the dissemination of results and facilitated discussions among researchers.

An event's greatest legacy…

07/13/2026  |  Nutraceutical Business Review

https://nutraceuticalbusinessreview.com/bioenergy-life-science-decentralised-clinical-research-nutraceutical 

The ingredient supplier says real-world decentralised studies can help brands generate finished-product evidence at lower cost while addressing growing regulatory expectations around substantiated health claims

Bioenergy Life Science (BLS) is expanding its use of decentralised clinical research as it looks to help nutraceutical brands generate finished-product evidence more cost-effectively amid increasing regulatory scrutiny of health claims.

The company says its approach will replace traditional site-based contract research organisation (CRO) studies with remote trials in which participants evaluate ingredients and finished products in their everyday environments.

According to the BLS, the model could significantly reduce study costs while producing data that better reflects real-world product use.

Michael Crabtree, General Manager at Bioenergy Life Science, believes the approach addresses a growing challenge for dietary supplement manufacturers.

"When companies want to use our products, we can now say they have been studied using gold-standard protocols such as double-blind, placebo-controlled trials, while being researched in everyday settings," he said.

"This enables our partners to build robust safety and efficacy dossiers at a fraction of the usual cost." The shift comes as regulators continue to emphasise that health-related marketing claims should be supported by competent and reliable scientific evidence.

In 2022, the US Federal Trade Commission (FTC) strengthened its guidance on substantiation for health product advertising, emphasising the need for evidence that directly…

07/13/2026  |  Karmanos Cancer Institute   |  PR Newswire

https://www.prnewswire.com/news-releases/karmanos-cancer-institute-rolls-out-new-oncology-clinical-trials-app-features-302823127.html 

New app functions empower patients, caregivers and health care professionals to easily find and access Karmanos' large portfolio of innovative cancer treatment options through actively recruiting clinical trials

The Barbara Ann Karmanos Cancer Institute has released a new and improved version of the KCI Clinical Trials App on both the Apple App Store and the Google Play Store. The apps' new features, launched on June 12, improve usability, accessibility and alignment with today's clinical and cancer research workflows throughout Karmanos Cancer Institute. Karmanos' Clinical Trials Office and research oncology technical support team designed new upgrades to provide a modernized platform to improve how patients, caregivers and health care professionals discover and engage with actively recruiting cancer clinical trials, leading to more informed treatment decisions.

"Updating this innovative application marks a pivotal moment for Karmanos. It reinforces our dedication to pioneering advances in cancer care and to providing our patients with treatment options that have shown promise and improved health outcomes. Karmanos has a unique offering of clinical trials that are not available at many hospitals, so when a patient is diagnosed with cancer, they should consider scheduling a second opinion with us," said Anthony Shields, M.D., Ph.D., associate center director of Clinical Science at Karmanos.

The app is popular among patients, their families and physicians. There are currently over 160 protocols listed on the portal and app, led…